Benfotiamine (fat-soluble vitamin B1)
Benfotiamine (Fat-Soluble Vitamin B1) · also known as Benfotiamine, Fat-soluble vitamin B1, S-benzoylthiamine monophosphate
Benfotiamine is a fat-soluble precursor of vitamin B1. Taken orally, it can raise thiamine levels and support transketolase activity. In randomized human trials it did not consistently lower the AGEs that were measured, and there is no consistent evidence of a clinical anti-glycation benefit.
Clinical uses and human evidence
Peripheral neuropathy (numbness and tingling)
Studies (2)
- Stracke 2008 · Exp Clin Endocrinol Diabetes · RCT · n=165 — Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study
- Ziegler 2026 · BMJ Open Diabetes Res Care · RCT · n=57 — Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy: a randomized, placebo-controlled, double-blind clinical trial (BOND study)
Age-related cognitive decline
Mechanisms of action
Blocking advanced glycation end products (AGEs) and protein cross-linking
After conversion to thiamine diphosphate, benfotiamine can support transketolase activity, shifting more glycolytic intermediates into the pentose phosphate pathway. Transketolase activity rose in a randomized human trial, but advanced glycation end products (AGEs) did not fall consistently.
Direct free radical trapping and chemical quenching
In vitro, benfotiamine can directly scavenge superoxide at concentrations of about 0.5–1 mmol/L, but free drug exposure after usual oral doses is far below that level. A direct free-radical scavenging effect has not been established in humans.